A PHASE 1B, 2-PART, DOUBLE-BLIND, PLACEBO-CONTROLLED, SPONSOR-OPEN STUDY, TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING (24-HOUR, PART 1) AND MULTIPLE ASCENDING (120-HOUR, PART 2) INTRAVENOUS INFUSIONS OF PF-07304814 IN HOSPITALIZED PARTICIPANTS WITH COVID-19
Latest Information Update: 08 May 2023
At a glance
- Drugs Lufotrelvir (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man
- Sponsors Pfizer
Most Recent Events
- 23 Jun 2021 Status changed from recruiting to completed.
- 12 May 2021 Planned End Date changed from 7 Jun 2021 to 15 Jun 2021.
- 12 May 2021 Planned primary completion date changed from 7 Jun 2021 to 15 Jun 2021.